One reason for the failure to directly target MYC, at least in SCLCs, is that, unlike the epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement in lung adenocarcinomas, MYC de-regulation is not a sole driver aberration. Here, EGFR is linked to lung adenocarcinoma.